General information and education, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Always consult a SEBI-registered adviser.
1. At a Glance
Quarter ended June 2026: standalone revenue ₹82.17 Cr against ₹60.02 Cr a year earlier, up 36.9%. Operating profit ₹5.08 Cr against ₹3.16 Cr. Net profit ₹4.19 Cr, up 46.0%. EPS ₹2.42.
The sequential comparison is the one that requires a second look. The March 2026 quarter produced operating profit of ₹0.22 Cr on revenue of ₹72.41 Cr — a 0.30% operating margin, which is the financial equivalent of running a 400-metre race and arriving back at the starting line. June 2026 came in at 6.18%. The line didn’t so much recover as remember it existed.
Around the numbers, the twelve months preceding this quarter were busy in the way that generates a lot of PDFs. The company announced a 51% acquisition of IDS Denmed for ₹128 crore in August 2025 and, on 8 May 2026, disclosed that both parties had mutually decided not to proceed. The CFO resigned in March 2026; a new one was appointed in May 2026. An independent director resigned on 7 August 2026. Crisil, which had parked the rating on Watch Developing through all of this, reaffirmed Crisil BBB and reattached a Stable outlook on 4 June 2026.
Meanwhile the underlying business kept doing the unglamorous thing: shipping dental consumables to dentists, 1.89 lakh orders’ worth in the quarter per the company’s investor update. Working capital days for FY26 stood at 189, up from 95.
2. Introduction
Vasa Denticity Limited was incorporated in 2016 and is promoted by Dr Vikas Agarwal and Mr Sandeep Aggarwal. It sells dental products — consumables, instruments, equipment and accessories — principally through the online portal Dentalkart.com and the Dentalkart mobile application. It listed on NSE Emerge under the symbol DENTALKART, raising ₹54.5 Cr through its IPO for working capital, brand-building spend, general corporate purposes and offer expenses. A subsequent preferential allotment raised ₹85 Cr from Malabar Investments and WhiteOak Capital Asset Management.
The growth curve since then has been the sort that makes founders talk in five-year numbers. Standalone revenue went ₹30.42 Cr (FY20) → ₹76.92 Cr (FY22) → ₹169.73 Cr (FY24) → ₹276.62 Cr (FY26). Crisil records a three-year revenue CAGR of around 31% to March 2026, attributing it to a rising SKU count, order inflow and a widening customer base.
The group has been acquiring subsidiaries the way it acquires SKUs. Waldent Innovations Pvt Ltd was established in August 2023; Smileworks Pvt Ltd, which delivers dental prostheses and restorations, was incorporated in November 2024; Dentalkart Distribution UK Limited appears in the consolidated results for the June 2026 quarter. Crisil consolidates VDL with Waldent and Smileworks as the VDL group.
Recent corporate events, in order: warrant conversion of ₹30.99 Cr by Malabar India Fund in August 2025 at ₹578 per share; an EGM in October 2025 that reclassified promoter-group shares to public category with 100% of votes in favour; the IDS Denmed withdrawal in May 2026; CFO transition from Mr Gaurav Aggarwal to Mr Sandeep Aggarwal effective 26 May 2026; and audited FY26 results approved 30 June 2026 with an unmodified auditor opinion. Mr Sandeep Aggarwal, co-founder and Whole-Time Director, was also re-appointed by rotation on 7 August 2026 and is disclosed as the brother of Dr Vikas Agarwal.
The FY26 annual number those events sit around: revenue ₹276.62 Cr, net profit ₹10.78 Cr.
US
Now live
US Stocks terminal is live
13,000+ US tickers · EDGAR fundamentals · screener and filings feed — the same terminal, for American markets.
Explore →
3. Business Model: WTF Do They Even Do?
They run an e-commerce store for teeth. Not the teeth themselves — the entire industrial hinterland behind them.
The catalogue is the business. Crisil counts around 470 domestic and international brands and more than 23,000 dental products, which means the warehouse contains more distinct objects than most people encounter in a calendar year, and nearly all of them are destined for a space roughly the size of a matchbox. The Screener commentary lists the core portfolio as consumables, small and large equipment, instruments, lab consumables and lab equipment, implants and aligners, plus specialty items including clear aligners and digital workflow tools. The specialisations run across orthodontics, endodontics, oral surgery, diagnosis, treatment and aesthetics — six disciplines, one shopping cart.
Revenue mix, disclosed for Q3 FY25: consumables 71.5%, equipment 23.4%, instruments 5.1%. So the machine that gets discussed at investor meetings is the equipment; the machine that pays the electricity bill is the box of burs. Management’s own framing in the August 2026 call is consistent with this — consumables carry the “highest” margins, while high-ticket digital and equipment gross margin sits at roughly 10–15%, and digital dentistry is positioned as a relationship driver that pulls recurring consumables behind it rather than as a margin product itself.
Roughly 30-plus of the brands are owned in-house, manufactured by third parties to specifications from the company’s R&D team. The rest is other people’s labels — Mani, 3M, Dentsply, Ivoclar, Woodpecker — plus non-branded product. In H1FY24 the company entered an exclusive agreement with Baldus Sedation GmbH & Co. KG, a German maker of nitrous oxide sedation systems, which is a sentence that explains itself and yet doesn’t.
Warehousing went from 100 sq ft in FY17 to 43,900 sq ft in FY25. In the August 2026 call, management said the warehouse count was reduced from seven to five, citing limited benefit from multiple warehouses inside the same logistics zone — a rare corporate initiative where the deliverable is fewer buildings.
The customer is the dentist: hospitals, clinics and medical establishments. Management’s stated addressable base is about 4 lakh registered dentists, 1 lakh dental students and
